Non-alcoholic fatty liver disease,diabetes medications and blood pressure  

作　　者：Ioannis Ilias Costas Thomopoulos 

机构地区：[1]Department of Endocrinology,Diabetes and Metabolism,Elena Venizelou Hospital,Athens 11521,Greece [2]Department of Cardiology,Elena Venizelou Hospital,Athens 11521,Greece

出　　处：《World Journal of Diabetes》2021年第10期1809-1811,共3页世界糖尿病杂志（英文版）（电子版）

摘　　要：New glucose-lowering agents reduce liver enzyme levels and blood pressure(BP).Whether this finding can be extended to non-alcoholic fatty liver disease(NAFLD)patients,in whom a bidirectional association of NAFLD measures and BP has been also demonstrated,remains by and large unknown.

关 键 词：Antidiabetic drugs Blood pressure reduction Non-alcoholic fatty liver disease Sodium glucose cotransporter 2 Alanine aminotransferase Aspartate aminotransferase 

分 类 号：R575.5[医药卫生—消化系统] R587.1[医药卫生—内科学]